The board of directors of US biotech major Biogen has elected Caroline Dorsa as chairwoman, effective immediately following the company’s 2023 Annual Meeting of Stockholders, set to take place on June 14, 2023.
Ms Dorsa will succeed current chairman Stelios Papadopoulos, who announced he would not stand for re-election.
Dr Papadopoulos said: “The entire board has great respect for Caroline and the tremendous contributions she has made during her 13-year tenure and as chair of our Audit Committee, where she has exhibited exceptional judgement, integrity, and dedication.
Ms Dorsa joined the Biogen board in 2010. She served as executive vice president and chief financial officer of Public Service Enterprise Group, a diversified energy company, from 2009 until her retirement in 2015, and served on its board of directors from 2003 to 2009.
Prior to that, she held various financial and operational positions over her 21 years at Merck & Co, including senior VP, global human health, strategy and integration, and VP and treasurer.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze